SCHEMBL5016099

SCHEMBL5016099

Nc1cc(-n2cccn2)nc(-c2cccnc2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.57
ADORA1 P30542 1/20 0.57
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 2/20 0.44
CCNK O75909 1/20 0.42
CDK12 Q9NYV4 1/20 0.42
CYP3A4 P08684 4/20 0.42
HSD17B10 Q99714 3/20 0.42
CYP2D6 P10635 3/20 0.42
CYP1A2 P05177 3/20 0.42
LMNA P02545 2/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NQO2 P16083 2/20 0.41
ADORA2B P29275 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TSHR P16473 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27661572 0.85 ADORA2A (0.61) ADORA2AADORA1ALDH1A1KDM4ECYP3A4
SCHEMBL5016199 0.83 CYP2A6 (0.47) ADORA2AADORA1ALDH1A1KDM4ECYP3A4
SCHEMBL5483640 0.82 ALDH1A1 (0.46) ADORA2AADORA1ALDH1A1KDM4ECCNK
SCHEMBL5017819 0.76 ADORA1 (0.55) ADORA2AADORA1ALDH1A1KDM4ELMNA
SCHEMBL5016110 0.76 ADORA2A (0.64) ADORA2AADORA1CYP3A4CYP1A2ADORA2B
SCHEMBL5024955 0.76 MAPT (0.52) ADORA2AADORA1ALDH1A1KDM4ECYP3A4
SCHEMBL1490006 0.75 ADORA2A (0.67) ADORA2AADORA1ALDH1A1KDM4ELMNA
SCHEMBL19830922 0.75 ADORA2A (0.59) ADORA2AADORA1ALDH1A1KDM4ECYP3A4
SCHEMBL5022230 0.74 ADORA2A (0.59) ADORA2AADORA1ALDH1A1KDM4ECYP3A4
SCHEMBL5016165 0.74 ADORA2A (0.52) ADORA2AADORA1CCNKCDK12CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
JP-2007514003-A 2007-05-31 JP claimed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP claimed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ALDH1A1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.